Rapid Micro Biosystems, Inc. RPID
We take great care to ensure that the data presented and summarized in this overview for RAPID MICRO BIOSYSTEMS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RPID
View all-
Bain Capital Life Sciences Investors, LLC Boston, MA8.43MShares$35.2 Million8.96% of portfolio
-
Kennedy Lewis Management LP New York, NY4.94MShares$20.6 Million20.16% of portfolio
-
Abg Wtt Global Life Science Capital Partners Gp LTD Hong Kong, F41.85MShares$7.71 Million100.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA965KShares$4.02 Million0.0% of portfolio
-
Parkman Healthcare Partners LLC Stamford, CT913KShares$3.81 Million0.38% of portfolio
-
Black Rock Inc. New York, NY649KShares$2.7 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY647KShares$2.7 Million0.01% of portfolio
-
Advent International Corp Boston, MA578KShares$2.41 Million0.07% of portfolio
-
Geode Capital Management, LLC Boston, MA205KShares$853,5440.0% of portfolio
-
Evernest Financial Advisors, LLC Carmel, IN200KShares$834,9750.21% of portfolio
Latest Institutional Activity in RPID
Top Purchases
Top Sells
About RPID
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Insider Transactions at RPID
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2025
|
Kirk Malloy Director |
SELL
Bona fide gift
|
Direct |
40,000
-58.31%
|
-
|
|
Oct 17
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,846
-0.35%
|
$20,538
$3.08 P/Share
|
|
Oct 17
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,233
+0.57%
|
$0
$0.75 P/Share
|
|
Jul 14
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
11,881
-1.21%
|
$35,643
$3.32 P/Share
|
|
Jul 14
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,145
+2.5%
|
-
|
|
Jul 11
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
11,874
-1.23%
|
$35,622
$3.33 P/Share
|
|
Jul 11
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,145
+2.53%
|
-
|
|
Jul 10
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
11,617
-1.22%
|
$34,851
$3.4 P/Share
|
|
Jul 10
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,145
+2.64%
|
-
|
|
Jul 09
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
11,247
-1.23%
|
$33,741
$3.51 P/Share
|
|
Jul 09
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,144
+2.68%
|
-
|
|
Jul 08
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
10,824
-1.21%
|
$32,472
$3.51 P/Share
|
|
Jul 08
2025
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,144
+2.73%
|
-
|
|
May 22
2025
|
Richard S Kollender Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,300
+11.41%
|
-
|
|
May 22
2025
|
Melinda Litherland Pei Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,300
+17.25%
|
-
|
|
May 22
2025
|
Inese Lowenstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,300
+27.03%
|
-
|
|
May 22
2025
|
Natale S Ricciardi Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,300
+33.33%
|
-
|
|
May 22
2025
|
Kirk Malloy Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,300
+15.39%
|
-
|
|
Mar 09
2025
|
John J. Addington Wilson CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
9,872
-4.07%
|
$19,744
$2.39 P/Share
|
|
Mar 09
2025
|
Sean M Wirtjes CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
7,690
-1.55%
|
$15,380
$2.39 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 641K shares |
|---|---|
| Open market or private purchase | 20K shares |
| Exercise of conversion of derivative security | 137K shares |
| Bona fide gift | 40K shares |
|---|---|
| Payment of exercise price or tax liability | 81K shares |
| Open market or private sale | 57.4K shares |